Ollin Biosciences raised $330 million in a Series B to advance a Phase 3 program for its Vabysmo challenger, targeting diabetic macular edema and wet age-related macular degeneration. The funding comes as the company prepares pivotal studies designed to test comparative advantage in a market with high clinical urgency and strong commercial expectations. TCGX and ARCH Venture Partners co-led the round, with participation from established biotech investors, a pension fund, and crossover investors. Ollin said the financing supports late-stage trial execution ahead of regulatory and commercialization decisions. For biotech investors, the round illustrates continued appetite for large Phase 3 risk when early clinical signals suggest differentiation in retina ADC/biologic-like competitive categories. (Article references: STAT+ and additional coverage on the same financing and trial plans.)